Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octaplex versus Beriplex for urgent reversal of vitamin K antagonist anticoagulation before surgery
2016-002649-41Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of coagulation factor X human and balfaxar (2 arms), sponsored by Octapharma. Primary endpoint: Hemostatic efficacy at end of surgery. Started Feb 2017; status: terminated.
02
Drugs
coagulation factor X humanbalfaxar
Beyond the preview
Go deeper on 2016-002649-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002649-41.